#### **1** Peripheral blood DNA methylation signatures predict response to

#### 2 vedolizumab and ustekinumab in adult patients with Crohn's

#### 3 disease: The EPIC-CD study

4 Vincent W. Joustra<sup>1\*</sup>, Andrew Y.F. Li Yim<sup>2,3\*</sup>, Peter Henneman<sup>3\*</sup>, Ishtu Hageman<sup>1,2</sup>, Tristan de

5 Waard<sup>4</sup>, Evgeni Levin<sup>4</sup>, Alexandra J. Noble<sup>5</sup>, Thomas P. Chapman<sup>5,6</sup>, Femke Mol<sup>2</sup>, Sarah

<sup>6</sup> van Zon<sup>1</sup>, Donghyeok Lee<sup>4</sup>, Colleen G.C. McGregor<sup>5</sup>, Alex T. Adams<sup>5</sup>, Jack J. Satsangi<sup>5\*\*</sup>,

7 Wouter J. de Jonge<sup>2,7\*\*</sup>, Geert R. D'Haens<sup>1\*\*</sup>; EPIC-CD Consortium.

8 EPIC-CD Consortium: Hans Paulich, Inge van Welsen, Rishand Ramkisoen, Yara Abeling, Marloes

9 Zwart, Nicole Berkers, Caroline Verseijden, Anje te Velde, Nicola Radcliffe, Aisling Quinn, Beatriz

10 Camesella Perez, Tom Thomas, Rahul Ravindran, James Chivenga, Simon Travis.

11

- <sup>1</sup>Amsterdam UMC University of Amsterdam, Department of Gastroenterology & Hepatology, Amsterdam, The
   Netherlands.
- <sup>2</sup>Amsterdam UMC University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The
   Netherlands.
- 16 <sup>3</sup>Amsterdam UMC University of Amsterdam, Genome Diagnostics Laboratory, Department of Human Genetics,
- 17 Amsterdam, The Netherlands.
- <sup>4</sup>Horaizon BV, Delft, The Netherlands.
- 19 <sup>5</sup>Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Translational Gastroenterology Unit
- 20 & NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.
- <sup>6</sup>Department of Gastroenterology, St Richard's and Worthing Hospitals, University Hospitals Sussex NHS
- 22 Foundation Trust, West Sussex, UK
- <sup>7</sup>University of Bonn, Department of Surgery, Germany.

24

- 25 \* These authors share first authorship
- 26 \*\* The 3 last authors are shared senior authors
- 27 Address for correspondence: Prof. Geert D'Haens PhD, Amsterdam University Medical Centers, Department of

28 Gastroenterology and Hepatology, Room C2-208, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

- 29 Email: g.dhaens@amsterdamumc.nl
- 30
- 31 *Funding:* This project was supported by a grant from the Helmsley Foundation [2019-1179]
- 32 Short title: DNA methylation predicts response to biologicals in CD
- 33 Acknowledgement: Floris de Voogd for his assistance in evaluation of ultrasound images.
- 34 Conflicts of interest: The AmsterdamUMC has a patent pending for the vedolizumab and ustekinumab response
- 35 prediction models presented in this manuscript. ALY received honoraria from Janssen, Johnson & Johnson,
- 36 DeciBio and was employed by GSK. WJ received honoraria from Janssen, Johnson & Johnson and is a
- 37 cofounder of AlBiomics BV. GD received speaker fees from Janssen, Johnson & Johnson. EL is a cofounder of

- 38 Horaizon BV and AlBiomics BV. The remaining authors disclose no conflicts. TC received honoraria from Janssen
- 39 and Takeda. The remaining authors have no conflicts of interest to declare.

# 40 Graphical abstract



## 45 **Abstract**

- 46 Biological therapeutics are now widely used in Crohn's disease (CD), with evidence of
- 47 efficacy from randomized trials and real-world experience. Primary non-response is a
- 48 common, poorly understood problem. We assessed blood methylation as a predictor of
- 49 response to vedolizumab (VDZ, anti-a4b7 integrin) or ustekinumab (USTE, anti-IL-12/23p40).
- 50 We report a two-center, prospective cohort study in which we profiled the peripheral blood
- 51 DNA methylome of 184 adult male and female CD patients prior to and during treatment with
- 52 VDZ or USTE in a discovery (n=126) and an external validation cohort (n=58). We defined
- 53 epigenetic biomarkers that were stable over time and associated with combined clinical and
- endoscopic response to VDZ or USTE with an area under curve (AUC) of 0.87 and 0.89,
- respectively. We validated these models in an external cohort yielding an AUC of 0.75 for
- 56 both VDZ and USTE. These data will now be prospectively tested in a multicenter
- 57 randomized clinical trial.

## 59 Introduction

60 Crohn's disease (CD) is an incurable, chronic, relapsing inflammatory bowel disease (IBD)

- 61 caused by a complex interplay between the environment, gut microbiome, and a
- 62 dysregulated immune system in genetically susceptible patients<sup>1,2</sup>. Accessibility to high-
- 63 throughput "omics" technology has enhanced our understanding of the underlying molecular
- 64 pathogenesis of CD leading to the development of several monoclonal antibodies or
- biologicals that target specific inflammatory pathways in an effort to suppress the
- 66 inflammation and to induce and or maintain a state of clinical and endoscopic remission<sup>3</sup>.
- 67 Currently, the repertoire of approved biologicals in CD includes anti-TNF antibodies
- (infliximab (IFX) and adalimumab (ADA)), the anti- $\alpha_4\beta_7$  integrin antibody vedolizumab (VDZ)
- and the anti-IL12/23p40 antibody ustekinumab (USTE). More recently, specific IL23p19
- antibodies and JAK inhibitors have also been approved for clinical use<sup>4-6</sup>. Despite the
- 71 established efficacy of these biological treatments to induce corticosteroid-free *clinical*
- *remission* in up to 65% of CD patients, sustained *endoscopic remission* is observed in not
- more than a third of patients after 1 year of treatment<sup>7-9</sup>. This creates a clinical challenge
- since therapeutic guidelines suggest to use endoscopic remission as a target. An
- increasingly common clinical scenario is the choice between VDZ or USTE as second-line

76 treatment for patients who have not responded to anti-TNF therapies.

77 To date, treatment selection has been based on a trial-and-error approach. Given the limited 78 efficacy, many patients are therefore treated with insufficiently effective treatment, which is 79 associated with an increased risk of complications (stenosis, fistula, abscesses, nutritional 80 deficiencies) and surgery. The development of strategies that allow selection of treatment 81 based on the likelihood of response is an important unmet need. Although various efforts using clinical<sup>10</sup>, transcriptomic<sup>11-13</sup>, proteomic<sup>14</sup> or microbial<sup>15,16</sup> technologies have been 82 83 investigated and reported, no predictive biomarkers have made their way to clinical 84 application<sup>17-19</sup>.

85 DNA methylation is one of the most studied epigenetic features characterized by the covalent 86 binding of methyl groups to nucleotides, most often a cytosine in a cytosine-phosphateguanine (CpG) sequence in humans<sup>20</sup>. DNA methylation is believed to play an essential role 87 88 in the regulation of gene expression, thereby determining cellular phenotype and behavior without altering the DNA sequence itself<sup>21,22</sup>. Within the context of IBD, DNA methylation has 89 90 gained particular interest due to its dynamic interaction with the environment and suggested epigenetic-microbial crosstalk<sup>23-25</sup>. A number of recent studies demonstrated differential DNA 91 92 methylation profiles associated with the presence of CD and/or specific CD-phenotypes<sup>26,27</sup> in

- peripheral blood leukocytes (PBL)<sup>28-30</sup>, intestinal mucosa<sup>31</sup> and specific cell-types thereof<sup>32,33</sup>.
- 94 Most studies proposed a potential role of the DNA methylome in diagnostics and prediction
- 95 of treatment response.
- In the current study we performed an epigenome-wide association study (EWAS) in which
- 97 we identified and validated prognostic DNA methylation signatures in peripheral blood of
- adult CD patients associated with objective therapeutic response to VDZ and USTE. We
- 99 subsequently interrogated whether these signatures were stable over time and assessed the
- 100 influence of common confounding variables. We further performed additional validation
- 101 analyses of the model against patients with previous non-response to one or both drugs.
- 102 Finally, we investigated the association of the identified DNA methylation biomarkers with
- 103 gene expression through transcriptomic analyses.
- 104

## 105 **Results**

#### 106 Study population

- 107 We prospectively recruited a discovery cohort of 126 adult patients at the IBD Center of 108 Amsterdam University Medical Centers (Amsterdam UMC), Amsterdam, Netherlands. All 109 patients had active symptomatic and endoscopic CD and were scheduled to start VDZ (N = 110 64) or USTE (N = 62). Evidence for active disease was documented with a validated clinical 111 score (Harvey Bradshaw Index (HBI), median 8 (interguartile range (IQR) 4-12)), biochemical 112 tests (serum C-reactive protein (CRP), median 6.1 mg/L (IQR 2.2-14.8) and fecal calprotectin 113 (FCP), median 903 µg/g (IQR 278-1816)) and also endoscopic signs of inflammation 114 measured with the simple endoscopic score for CD (SES-CD), median 9 (IQR 6-15). In 115 addition, an external validation cohort of 58 adult CD patients starting VDZ (N = 25) or USTE 116 (N = 33) biological therapy were recruited at the John Radcliffe Hospital, Oxford, United 117 Kingdom. Peripheral blood leukocyte (PBL) samples were obtained prior to treatment 118 initiation and upon response assessment at a median of 27 (IQR 20-33) weeks into
- 119 treatment, when patients were classified as responder (R) or non-responder (NR). A detailed
- 120 overview of all the clinical characteristics across the different cohorts and treatments can be
- 121 found in the methods section as well as in **Table 1**.

## 122 Blood DNA methylation profiling predicts response to vedolizumab and

#### 123 **ustekinumab**

- To identify prognostic biomarkers of VDZ and USTE response, we performed supervised 124 machine learning through stability selected gradient boosting<sup>34,35</sup> on blood samples obtained 125 126 shortly before the start of treatment (Fig. 1a). The model was trained on the discovery cohort 127 acquired in Amsterdam and subsequently validated in the validation cohort acquired in 128 Oxford. We were able to generate response-predicting models with an area under the curve 129 (AUC) of 0.87 with a standard deviation of 0.06 and 0.89 with a standard deviation of 0.08 for 130 VDZ and USTE, respectively, when testing against the discovery cohort (Fig. 1b). The 131 models comprised 25 and 68 differentially methylated CpGs for VDZ and USTE, respectively 132 (Fig. 1c, Supplementary Fig. 1-2 and Supplementary Tables 1-2). Validating our models 133 against the independent validation cohort yielded an AUC of 0.75 for both VDZ and USTE 134 (Fig. 1b), indicating reproducible response-associated differences in DNA methylation prior
- 135 to the start of treatment.
- While the discrepancy between discovery and validation performances is expected as part ofmachine learning, we hypothesized that the differences were partially due to differences in

response assessments. During the COVID-19 pandemic, endoscopic assessments were

- 139 scheduled less frequently resulting in the validation cohort consisting of patient samples in
- 140 whom response was defined on both strict (combined clinical-, biochemical- and endoscopic
- 141 evaluation) or modified criteria (combined clinical- and biochemical evaluation). We therefore
- 142 investigated whether a difference in performance could be observed between both methods
- of evaluation. This stratification indicated that accuracy was optimized by using the strictly
- defined combination of clinical- and endoscopic endpoints for both VDZ (AUC<sub>strict</sub> = 0.83
- 145 versus  $AUC_{modified} = 0.66$ ) and USTE ( $AUC_{strict} = 0.83$  versus  $AUC_{modified} = 0.72$ )
- 146 (Supplementary Fig. 3a). Application of the strict criteria yielded performances similar to the
- 147 discovery dataset thereby confirming that our model is likely more capable at predicting
- response as defined using combined clinical-, biochemical- and endoscopic evaluations.
- 149 In addition, we were interested whether the performance of our models was affected by prior
- 150 exposure to anti-TNF medication. We observed a better performance of our models among
- anti-TNF naïve compared to anti-TNF exposed patients for both VDZ (AUC<sub>non-exposed</sub> = 0.85
- versus  $AUC_{exposed} = 0.66$ ) and USTE ( $AUC_{non-exposed} = 0.97$  versus  $AUC_{exposed} = 0.63$ )
- 153 (Supplementary Fig. 3b).

154 Focusing on the practical implications in a clinical setting, we calculated a sensitivity of 0.769 155 and a specificity of 0.67 for VDZ and both a sensitivity and specificity of 0.73 for USTE 156 (Table 2). Next, we computed the likelihood ratio of response and the post-test probability of 157 response to aid clinicians in accurately predicting response following a positive test outcome. From Lowenberg et al.<sup>7</sup>, we note that 50 of the 110 VDZ-treated CD patients presented with 158 159 endoscopic response at week 52 indicating a pre-test probability of response of 0.45. At the 160 calculated sensitivity of 0.77 and a specificity of 0.67, the likelihood ratio of response is 2.31, 161 thereby making the post-test probability of response 0.65 for VDZ. Similarly, for USTE, prior research showed that 75 of the 179 USTE-treated CD patients presented with endoscopic 162 response at week 52<sup>8</sup>, indicating a pre-test probability of response of 0.42. At the calculated 163 164 sensitivity and specificity of 0.73 the likelihood ratio is 2.67 and the post-test probability of 165 response is 0.66. Taken together, the probability that a patient would actually respond to 166 VDZ or USTE when classified as responder is 0.20 and 0.24 higher than the current standard 167 of care.

#### 168 Methylation status of predictor CpGs remains stable over time

169 As baseline samples were acquired pre-treatment, we sought to understand whether the

- initiation of treatment affected the methylation status of the predictor CpGs. To this end, we
- 171 compared samples obtained at the time of response assessment (T2) with samples obtained

172 pre-treatment (T1). We could not identify any statistically significant differences in DNA methylation levels for any of the predictor CpGs (Fig. 2a). Indeed, comparing the differences 173 174 over time suggested that the mean difference between R and NR was similar both pre-175 treatment and at response assessment (Fig. 2b). Furthermore, a two-way, mixed, 176 consistency intra-class correlation (ICC) analysis indicated highly-stable DNA methylation 177 over time with 24 out of 25 VDZ and 62 out of 68 USTE predictor CpGs presenting ICC 178 values ≥0.75 (Fig. 2c, Supplementary Fig. 1 and 2). This observation was corroborated by 179 interrogating our previous longitudinal consistency analysis of peripheral blood DNA methylation from 46 adult IBD patients collected at 2 time points with a median of 7 years 180 (range, 2-9 years) in between<sup>36</sup>. Here, we observed that the majority (16 out of 25 VDZ and 181 52 out of 68 USTE) of the predictor CpGs presented "good" ( $0.75 \le ICC < 0.9$ ) to "excellent" 182 183  $(0.9 \ge ICC)$  stability<sup>37</sup> over a median span of 7 years (**Fig. 2c**). As a final validation, we 184 utilized the prognostic model to predict response to therapy of the samples obtained at 185 response assessment, where we obtained better performances compared to the pre-186 treatment samples (AUC<sub>VDZ</sub> = 0.97; AUC<sub>USTE</sub> = 1.00) (**Fig. 2d**). Altogether, our observations 187 suggest that response-associated differences in DNA methylation detected prior to treatment 188 remain stable during treatment.

# Patients who previously experienced treatment failure to multiple biological treatments are classified correctly

191 Having established that the prognostic response prediction models for both drugs perform 192 well both pre- and into treatment, we explored the performance of our model in a further 193 independent cohort of 33 adult CD patients from whom blood had been collected after 194 sequential treatment with anti-TNF, VDZ, and/or USTE. Treatment failure was determined 195 with endoscopy in 28 (82%), MRI in 2 (6%), or the need for surgical resection in 4 (12%), 196 combined with biochemical biomarkers such as CRP in 12 (35%) and/or FCP in 16 (47%) 197 and clinical parameters in 32 (94%) patients. In this cohort, a relatively large proportion of 198 patients had extensive disease location (67.6%), perianal disease (52.9%), and/or IBD-199 related surgery (70.6%) in the past (Supplementary Table 3).

Both VDZ and USTE response prediction models accurately predicted NR, with 24 out of 27
(88.9%) VDZ-NR patients and 24 out of 26 (92.3%) USTE-NR patients correctly identified.
Focusing specifically on the patients with previous non-response to both VDZ and USTE the
models correctly classified 16 out of 19 (84%) as NR. Notably, 12 of out of these 19 patients
(75%) were anti-TNF experienced.

#### 205 Assessment of potential confounding variables

206 Through multiple linear regression analyses we observed that 22 of the 25 (88%) VDZ 207 response-associated CpGs and 38 of the 68 (55%) USTE response-associated CpGs (Fig. 208 **3a** and **Supplementary Fig. 1-2**) presented statistically significant differences. The large 209 discrepancy between the linear regression analyses and the USTE response-associated 210 CpGs indicates that a more complex non-linear relationship exists among the response-211 associated predictor CpGs and underscores that statistical p-values may not equal biologic 212 or functional relevance and/or importance at an individual level. As it has been established 213 that the peripheral blood DNA methylome is associated with certain phenotypic 214 characteristics such as sex, age, smoking status, as well as the underlying cellular 215 composition<sup>38-41</sup>, we investigated whether any of these variables confounded our results. In 216 doing so with linear regression analysis, we observed that 12 out of 22 (55%) and 30 out of 217 38 (79%) markers remained significantly associated with response for VDZ and USTE, 218 respectively (Fig. 3a). In terms of effect size, the mean percentage methylation difference 219 between R and NR of the predictor CpGs on average decreased by 15% and increased by 220 5% in VDZ and USTE, respectively (Fig. 3b). To understand whether the confounding 221 variables are capable of predicting response, we constructed a prediction model solely based 222 on the confounding variables using the discovery cohort and tested this on the validation 223 cohort. The confounder model yielded an AUC of 0.57 and 0.65 for VDZ and USTE, 224 respectively, against the validation cohort indicating worse performance than the prediction 225 model based on CpGs only (Fig. 3c). Our results indicate that while there appears to be a 226 significant association with sex, age, smoker status and blood cell distribution, the CpG-only 227 prediction model outperforms a confounder-only model.

- 228 We next investigated whether the predictor CpGs were significantly associated with severity
- of systemic and intestinal inflammation at baseline measured using CRP and FCP, as was
- previously reported by Somineni *et al.*<sup>42</sup>. For VDZ, 5 predictor CpGs significantly associated
- with CRP whereas only a single CpG was associated with FCP (Supplementary Fig. 4). For
- 232 USTE, we observed 9 predictor CpGs associated with CRP and 2 predictor CpGs with FCP
- 233 (Supplementary Fig. 4). In all cases, mean differences in methylation were smaller than
- 234 0.5%. These observations suggest that the majority of the identified predictor CpGs are
- 235 independent of inflammatory status at onset of therapy.

# RFPL2 presents concordant response-associated differential methylation and expression

To understand the functional relevance of the predictor CpGs, we annotated the them to their respective genes based on whether they were located in either a gene promoter or enhancer

240 resulting in the annotation of 20 VDZ response-associated predictor CpGs to 16 unique 241 genes (Supplementary Table 1) and 43 USTE response-associated predictor CpGs to 46 242 genes (Supplementary Table 2). We performed transcriptomic analyses on a subset of 243 samples from the discovery cohort (VDZ;  $N_{T1}=10_R 10_{NR}$ ,  $N_{T2}=10_R 8_{NR}$  and USTE;  $N_{T1}=14_R 11_{NR}$ ,  $N_{T2}=10_R9_{NR}$ ). Comparing R with NR identified pretreatment differences for predictor CpG-244 245 associated genes TULP4 (p-value<sub>T1</sub> = 4.38E-02) and RFPL2 (p-value<sub>T1</sub> = 4.72E-02) for VDZ 246 (Fig. 4a, b and Supplementary Table 4), with RFPL2 presenting a significant inverse 247 correlation between DNA methylation and gene expression (Pearson r = -0.65; p-value = 248 1.39E-03) (Fig. 4c). For USTE, we observed significant differences in the expression of 249 predictor CpG-associated genes MRC1 (p-value<sub>T1</sub> = 4.25E-04) and TMEM191B (p-value<sub>T1</sub> = 7.31E-03) (Fig. 4a and d and Supplementary Table 5) with TMEM191B presenting a 250 251 significant positive correlation between DNA methylation and gene expression (Pearson r = 252 0.57; p-value = 3.11E-03) (Fig. 4e). We next investigated whether predictor CpG-associated 253 genes presented differential expression after the start of treatment by comparing R with NR 254 at response assessment. VDZ predictor CpG-associated genes MCM2 (p-value<sub>T2</sub> = 2.40E-255 03) and RFPL2 (p-value<sub>12</sub> = 3.88E-03) were differentially expressed at response assessment 256 (Fig. 4a, f and Supplementary Table 4) with RFPL2, once again, presenting a significant 257 inverse correlation between DNA methylation and expression (Pearson r = -0.55; p-value = 0.017) (Fig. 4g). For USTE, predictor CpG-associated genes POTEF (p-value<sub>T2</sub> = 1.47E-02), 258 259 HDAC4 (p-value<sub>T2</sub> = 2.18E-02), PARP4 (p-value<sub>T2</sub> = 3.49E-02) and MARK3 (p-value<sub>T2</sub> = 260 2.87E-02) presented differential expression at response assessment (Fig. 4a, h and 261 **Supplementary Table 5**), but did not show any significant correlation with DNA methylation. 262 Taken together, our results show that some of the response predictor CpG-associated genes 263 present differential expression either pretreatment and/or during response assessment, with 264 VDZ- and USTE- response-associated genes RFPL2 and TMEM191B, respectively, 265 presenting a significant correlation between DNA methylation and gene expression. 266 Nonetheless, we acknowledge that most predictor CpG-associated genes present no 267 response-associated differential expression.

## 269 **Discussion**

- 270 Although the introduction of biologicals has transformed the care of patients with CD, the
- 271 current clinical practice of treatment selection remains suboptimal. Nonetheless, a large body
- 272 of real-world evidence studies suggests there could be a place for a more individualized
- 273 approach<sup>43,44</sup>. Therefore, in parallel with ongoing drug development, predictive biomarkers
- that allow for selection of successful medical therapy would represent a major step forward in
- 275 clinical care.
- 276 Here, we conducted a longitudinal case-control study where we identified methylation
- signatures composed of 25 and 68 markers associated with combined endoscopic,
- 278 biochemical and clinical response to VDZ and USTE, respectively, in a cohort of adult CD
- 279 patients in whom treatment response was assessed with stringent criteria. We were able to
- build models with significant predictive performance at an AUC > 0.85 for both models. The
- 281 models demonstrated similar performance in an independent, external validation with an
- AUC of 0.75 for both models.
- 283 Recent real-world data and (post-hoc) findings from both the GEMINI and UNITI trials indicate superior response to both VDZ and USTE in anti-TNF naïve patients<sup>45-49</sup>. In our 284 discovery cohorts, 77% of VDZ and 98% of the USTE-treated patients were previously 285 286 exposed to anti-TNF medication. Stratifying the patients in the validation cohort by previous 287 anti-TNF exposure showed that both models performed noticeably better in anti-TNF naïve 288 rather than exposed patients. However, the number of patients included in both subset 289 comparisons are relatively small and further exploration using larger groups patients are 290 needed. Furthermore, we demonstrate the ability of our models to effectively identify patients 291 with previous non-response to both VDZ and USTE treatment. This holds true for both anti-292 TNF naïve and experienced patients, providing significant importance for clinical practice, as 293 the precise prediction of non-response to both drugs offers clinicians the opportunity to make 294 informed decisions. For anti-TNF experienced patients, this could mean a direct switch 295 towards newer modes-of-action (i.e. JAK-inhibitors).

While this study is the first to demonstrate the utility of DNA methylation profiling in whole blood for objective response to VDZ and USTE in CD patients, previous analyses from two separate studies explored its application to predict anti-TNF response in both CD and UC patients<sup>50,51</sup>. In the first study, the authors sought to identify an anti-TNF response-associated profile combining integrated methylation and gene expression data from samples taken before and 2 weeks into treatment using a primary endpoint of clinical remission at week 14<sup>50</sup>. The observations were made using a mixed cohort of 37 IBD (18 CD, 19 UC) patients 303 and validated against a publicly available gene expression data of 20 CD patients. In the 304 second study, the authors did not show replication of these observations using methylation 305 data of 385 patients, as part of the previously published PANTS study<sup>51,52</sup>. In this study, bionaïve patients with active CD started treatment with adalimumab or infliximab. Interestingly, 306 307 the authors report 323 differentially methylated positions annotated to 210 genes identified at 308 baseline that were significantly associated with serum drug concentrations at week 14. This 309 profile could potentially be of interest to identify patients in need of intensified anti-TNF drug 310 monitoring or dosing. The methodological differences and lack of endoscopic data in the 311 previous experiments preclude direct comparison with our study in which outcome 312 assessments were more stringent.

313 Through two separate stability analyses, we demonstrated both short- and long-term hyper

314 stability of the majority of our identified CpG markers indicating their independence of

treatment as well as the resultant difference in inflammation. The latter is further evidenced

by the lack of correlation between the methylation status of the predictor CpGs and both

baseline CRP and FCP, therapy switch or even CD-related surgery<sup>53</sup> suggesting that the

318 CpGs are response-predictors but do not directly mediate inflammation. Nonetheless,

319 confounder analysis indicated potential confounding for some of the predictor CpGs for age,

320 sex, smoking status and the blood cell distribution. We observed however that prediction

321 modeling using the confounders only performed significantly worse than the CpG model,

322 indicating that confounders do not contribute substantially to the predictive performance.

We note that the predictor CpGs annotate to genes associated with MHC class I (*HLA-C*)

and cell migration (*TSPEAR*, *NID*2)<sup>54,55</sup> for VDZ and macrophage function (*RHOJ*, *MARK*3

and *PCGF3*)<sup>56-61</sup> and polarization (*PKNOX1* and *MRC1*)<sup>62-64</sup>, histone remodeling and Th17-

326 differentiation (*HDAC4*)<sup>65-69</sup> and TGF- $\beta$  signaling (*SMAD1* and *EBF3*)<sup>70-77</sup> for USTE.

327 Integrating DNA methylation with their transcriptomic data indicates that VDZ-response-

associated *RFPL2*, which encodes an E3 ubiquitin ligase<sup>78,79</sup>, and USTE-response-

329 associated *TMEM191B*, which encodes a transmembrane protein, present concordant

330 differential methylation and expression. However, their exact role in either IBD and/or

331 response to therapy remains unknown to date. Accordingly, beyond the utility of the predictor

332 CpGs in classifying response to therapy, identifying their role in the pathogenesis and

etiology of non-response remains challenging at present and hence a subject for future

334 studies.

335 Our study derives its main strength from the sampling and endpoint assessment strategy. In

addition, patients with anti-drug antibodies or without a measurable serum drug

337 concentration and those that stopped treatment due to adverse events were excluded prior to

338 the selection of this cohort. Non-responders therefore reflect a more homogenous group of 339 true biological (i.e. pharmacodynamic) non-response rather than failure due to 340 pharmacokinetics or intolerance. Second, the relatively small sample size was justified by 341 performing a sample size estimation based on prior pilot experiments in combination with previous studies on statistical power in EWAS<sup>80</sup>. Lastly, besides stability of the observed 342 343 methylation differences during induction- and maintenance treatment, our markers 344 demonstrated stable differences between R and NR over time, which was further 345 corroborated when interrogating our 7-year longitudinal DNA methylation survey. This time-346 independent behavior of the predictor CpGs indicates that exposure over time and change in 347 inflammatory parameters does not affect the response-associated behavior of the CpGs,

348 suggesting that the CpGs are very stable, which in turn increases its utility in clinical practice.

349 There are however some limitations to this study. First, a post-hoc power analysis of the 350 mean effect size difference between responders and non-responders indicated a mean 351 absolute difference of 9.9% and 7.6% for VDZ and USTE, respectively. At the collected 352 samples sizes, this would translate to a statistical power of approximately 98.4% and 64.3% for VDZ and USTE, respectively<sup>80</sup>. Despite the lower power for USTE, we note that the model 353 354 remained performant in predicting response in the external cohort. Second, in the external 355 cohort response assessment was less stringent in approximately 70% of the patients due to 356 the COVID-19 pandemic during which we encountered a notable reduction in the access to non-essential endoscopies, particularly in the UK<sup>81</sup>. Nonetheless, the modified response 357 358 criteria are a reflection of clinical parameters that physicians commonly use in daily practice. 359 This pragmatic approach enhances the overall generalizability of our results to a much larger 360 IBD population. Notably, the analysis where we included the available endoscopic outcomes 361 in the subset of UK patients for whom these data were available, enhanced the performance 362 to an AUC of 0.83 for both the VDZ and USTE models, reinforcing the validity of both models 363 in identifying objective responders to these biological therapies. While we acknowledge this 364 limitation, we believe that our comprehensive approach provides valuable insights into the 365 predictive capabilities of the models under diverse clinical scenarios. Third, while we 366 purposely used PBL samples as these are minimally invasive and easily obtained during daily clinical practice, PBL represents a mixed cellular population. Therefore, the specific cell 367 types responsible for the observed predictive signal remain unidentified<sup>82</sup>. It should be noted 368 369 however that after correcting for the blood cell distribution, several predictor CpGs remained 370 statistically significant, indicating independence of cellular composition. Third, the majority of 371 the predictor CpG loci identified are situated within gene introns, complicating the biological 372 interpretation of our findings. Although the identified predictor CpGs collectively serve as a 373 strong predictor of response, we acknowledge that the underlying biology behind this

374 observation is more complicated than merely the inverse correlation between DNA

- 375 methylation and gene expression. Lastly, while strict removal of most catalogued and
- 376 predicted genetic variant-binding probes, we acknowledge that there is still a possibility that
- 377 underlying genetic differences could have influenced our outcome<sup>83</sup>. Nonetheless both
- 378 models performed effectively in both the discovery- (Dutch) and the validation (UK) cohorts.

In summary, our findings pave the way towards personalized medicine for CD. Several US

- and European studies report a significant reduction in pharmaco-economic burden of CD if
- 381 clinical and endoscopic remission can be achieved with adequate treatment compared to the
- cost of treatment of IBD patients on suboptimal medication<sup>84-88</sup>. In the absence of a predictive
- biomarker panel, current endoscopic response rates at week 52 have been reported around
- 45% in VDZ and 42% in USTE treated CD patients<sup>7,8</sup>. Taken together, our biomarker panels
- 385 could potentially increase these proportions by approximately 20% for VDZ and 24% for
- USTE, thereby significantly impacting healthcare costs and disease burden in these patients.
- 387 We acknowledge that clinical validation of our findings in a randomized prospective trial,
- 388 comparing our method of pre-treatment selection with current clinical practice, is needed to

firmly demonstrate both clinical and economic benefit<sup>89</sup>. To this end, the Omicrohn trial as

- 390 part of the ongoing Horizon Europe funded METHYLOMIC project has been launched and is
- 391 currently underway<sup>90</sup>.

## **393** Online Methods

#### 394 Study population and design

395 We prospectively recruited adult male and female CD patients that presented with a

combination of clinical, biochemical and endoscopic disease activity at ileo-colonoscopy and

397 were scheduled to start VDZ or USTE treatment within 1 year after the last endoscopy at the

398 Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands

399 (discovery cohort) and the John Radcliffe Hospital, Oxford, United Kingdom (validation

400 cohort). All patients were naïve to the biological of interest.

401 Patients were treated according to standard-of-care protocols, which for VDZ meant that

402 patients were given 300 mg infusions at week 0, 2 and 6 followed by infusions at an 8 week

403 interval. For USTE, standard-of-care involved patients receiving a single intravenous infusion

404 (6 mg/kg rounded to 260 mg, 390 mg or 520 mg) at week 0 and subsequent 90 mg

405 subcutaneous injections at an 8 week interval. For both VDZ and USTE, interval

406 intensification every 6 or 4 weeks with an additional week 10 infusion for VDZ or extra

407 intravenous boost infusion for USTE at the treating physicians' discretion. To ensure

408 assessment of mechanistic and not pharmacokinetic failures of each biological treatment,

409 only patients with measurable serum concentrations without anti-drug antibodies at response

410 assessment were used for methylation analyses.

411 The project was approved by the medical ethics committee of the Academic Medical Hospital

412 (METC NL57944.018.16 and NL53989.018.15) and written informed consent was obtained

413 from all subjects prior to sampling, as well as by the National Health Service Research Ethics

414 committee. (REC reference: 21/PR/0010 Protocol number: 14833 IRAS project ID: 266041).

415 UK patients were recruited and consented under the ethics of the Translational

416 Gastrointestinal Unit biobank IBD cohort ethics (09/H1204/30) and GI cohort ethics

417 (16/YH/0247 and 21/YH/0206). The quality of the collected data and study procedures were

418 assessed by an independent monitor.

### 419 Vedolizumab discovery and validation cohort characteristics

420 The VDZ discovery cohort consisted of 64 patients ( $N_R = 36$ ,  $N_{NR} = 28$ ) of which 49 (77%) had

421 previously been exposed to anti-TNF treatment and 9 (14%) to USTE. Response was

422 defined on endoscopic as well as clinical/biochemical criteria in this group (see section

423 "Definitions of response"). In 62 (97%) patients, a follow-up endoscopy was performed. The

424 remaining 2 patients were classified as non-responders as a result of urgent surgical

425 intervention due to worsening of disease without CD-associated complications, such as

- 426 stenosis or perforating disease. R and NR presented overall comparable clinical
- 427 characteristics, with no significant differences in age, sex and smoking behavior. Importantly,
- 428 serum VDZ concentrations at T2 were not significantly different between R and NR (median
- 429 15 (IQR 7.7-20.5) versus median 14 (IQR 3.6-27.5), p-value = 0.77) although more NR
- 430 patients received an additional VDZ infusion at week 10 (35.7% vs 13.9%, p-value = 0.04).
- 431 Notably, patients in the NR group had more frequently been exposed to anti-TNF treatment
- 432 (89.3% vs 66.7%, p-value = 0.03) and/or USTE (25% vs 5.6%, p-value = 0.03) compared to
- 433 R group. Thirteen of the 15 R patients received VDZ as first-line biologic, had a shorter
- disease duration, lower rates of previous surgery and perianal disease as well as a higher
- 435 percentage of B1 phenotype compared to anti-TNF experienced patients.
- 436 The VDZ validation cohort consisted of 25 additional patients ( $N_R = 14$  and  $N_{NR} = 11$ ) from
- 437 Oxford with a median 9 (IQR 3-15) year disease duration. Seventeen (68%) did not undergo
- a follow-up colonoscopy to assess endoscopic response due to restrictions during the
- 439 COVID-19 pandemic and therefore were assessed using the modified definition of response,
- 440 which was defined as a combination of clinical and biochemical parameters (see "Definitions
- 441 of response" below). Out of these 25 patients, 13 (52%) were biological naïve, 12 (48%)
- 442 were anti-TNF-experienced and 7 (28%) were previously treated with USTE, which was
- enriched among the NR group (54.5% vs 7.1%, p-value = 0.01). All other clinical
- 444 characteristics were comparable in R and NR, including age, sex, and smoking behavior. As
- in the VDZ discovery cohort, the majority (69%) of biological naïve patients were respondersto VDZ.

#### 447 Ustekinumab discovery and validation cohort characteristics

- 448 The USTE discovery cohort consisted of 62 patients ( $N_R$ =30,  $N_{NR}$ =32) of which 60 (98%)
- 449 were previously exposed to anti-TNF and 26 (42%) to VDZ. A follow-up endoscopy was
- 450 performed in 58 (94%) patients. The remaining 4 were evaluated with serial intestinal
- 451 ultrasound using validated criteria assessed by an expert IBD ultrasonographist. Clinical
- 452 characteristics did not significantly differ between R and NR, although the R population
- 453 consisted of more female patients (R = 80%, NR = 56.3%, p-value = 0.05). No significant
- differences in treatment intensification (21.9% vs 6.7%, p-value = 0.08), extra intravenous
- 455 boost infusions (p-value = 0.26) or serum USTE concentrations at T2 between R and NR
- 456 were observed (median 3.0 (IQR 1.8-5.5) versus median 4.8 (IQR 2.1-8.6), p-value = 0.31).
- 457 The USTE validation cohort consisted of 33 patients ( $N_R$ =22 and  $N_{NR}$ =11), with a median
- disease duration of 11 (IQR 3-20) years. Twenty-five (76%) did not undergo follow-up

- 459 colonoscopy as a result of pandemic-related restrictions on non-essential endoscopy and
- therefore were assessed using the modified definition of response. Of the 33 included
- 461 patients, 9 were biological naïve (52%), 21 (63.6%) were anti-TNF-experienced and 5
- 462 (15.2%) were previously treated with VDZ. Responders presented a significantly longer
- disease duration compared to non-responders (median 15 vs 5 years, p=0.05). No significant
- differences in age, sex, and smoking behavior were observed.

#### 465 Sample collection and storage protocols

- In all patients, whole peripheral blood leukocyte (PBL) samples were collected for
- 467 measurement of epigenome-wide DNA methylation prior to the start of VDZ/USTE, before
- the baseline endoscopy or the first infusion (time point 1) and after an interval of 6-9 months
- 469 into treatment (time point 2) using 4.0-6.0mL BD ethylenediaminetetraacetic acid (EDTA)
- 470 vacutainer tubes. For the Amsterdam discovery cohort, samples were subsequently
- 471 aliquoted into 1.10mL micronic tubes before storing at -80 °C until further handling. The
- 472 Oxford validation samples were directly frozen at -80 °C in preparation for later extraction. At
- both time points, additional PBL samples were stored for the purpose of targeted gene
- 474 expression analyses from a subset of the Amsterdam discovery patients using 2.0-mL
- 475 PAXgene Blood RNA tubes and were frozen at -20 °C for 24 h before storing at -80 °C until
- 476 further handling.

#### 477 **Definitions of response**

- 478 At response assessment, patients were classified as responders (R) or non-responders (NR)
- 479 based on a strict combination of endoscopic, biochemical and clinical criteria: ≥50%
- 480 reduction in the endoscopic SES-CD score, corticosteroid-free clinical remission (≥3 point
- 481 drop<sup>91</sup> in HBI or HBI ≤4 and no systemic steroids) and/or biochemical response (CRP
- 482 reduction ≥50% or CRP≤5 mg/L and FCP reduction ≥50% or FCP ≤250 μg/g). Modified
- 483 response was defined as a combination of corticosteroid-free clinical- (HBI ≤4) and
- biochemical (CRP  $\leq$ 5 mg/L and/or FCP  $\leq$ 250 µg/g) remission between week 26-52 without
- treatment change through week 52.

#### 486 **DNA isolation and in vitro DNA methylation analysis**

- 487 For the Amsterdam discovery cohorts, genomic DNA was extracted using the QIAsymphony.
- 488 We next assessed the quantity of DNA using the FLUOstar OMEGA and quality of the high-
- 489 molecular weight DNA on a 0.8% agarose gel. Following these steps, 750ng of DNA per
- 490 sample was randomized per plate, to limit batch effects, after which genomic DNA was

- 491 bisulfite converted using the Zymo EZ DNA Methylation kit and analyzed on the Illumina
- 492 HumanMethylation EPIC BeadChip array. Aforementioned work was performed at the Core
- 493 Facility Genomics, Amsterdam UMC, Amsterdam, the Netherlands.
- 494 For the Oxford validation cohorts, genomic DNA was extracted using the Qiagen Puregene
- Blood Core Kit C at the Oxford Translational Gastroenterology Unit, University of Oxford.
- 496 DNA samples were assessed for quality using the NanoDrop spectrometer (NanoDrop 1000,
- 497 Thermo Scientific). A total of 750ng of DNA per sample was randomized per plate, to limit
- 498 batch effects, after which genomic DNA was bisulfite converted using the Zymo EZ DNA
- 499 Methylation kit and analyzed on the Illumina HumanMethylation EPIC BeadChip array at
- 500 UCL Genomics, University College London, London, United Kingdom.

#### 501 Raw methylation data pre-processing

DNA methylation data processing was orchestrated in Snakemake (v7.14.1)<sup>92</sup>. Raw 502 503 methylation data was imported into the R statistical environment (v4.3.1) using the Bioconductor minfi<sup>93,94</sup> package (v1.44). Quality control was performed using shinyMethyl 504 (v1.38.0)<sup>95</sup> for probe level quality control, ewastools (v1.7.2)<sup>96</sup> to ensure paired samples were 505 correctly labeled, and the Horvath clock<sup>97</sup> to ensure a proper match with the metadata. One 506 507 patient sample from the VDZ and one patient sample from the USTE discovery cohort were 508 removed due to a discrepancy in the predicted sex with the annotated sex. Raw signals were normalized using functional normalization<sup>98</sup>. Probes were annotated to their gene of interest 509 510 using the provided Illumina annotations, which were further enhanced with enhancer data as 511 obtained using the publicly accessible promoter-capture Hi-C data<sup>99</sup>. We subsequently calculated the methylation signal in the form of percentage methylation. Technical artefacts 512 513 as a result of batch, plate and plate position were removed using ComBat (v0.9.7)<sup>100</sup> as implemented in the sva (v3.50.0)<sup>101</sup> package, a tool for removing known batch effects in 514 microarray data using the parametric empirical Bayes framework, using the default 515 516 parameters. Probes hybridizing to allosomes were removed to identify sex-independent 517 differences. Moreover, probes hybridizing to known and tentative genetic variants were 518 removed to identify true methylation signals. Known genetic variants were identified based 519 on their presence in dbSNP (v137), whereas tentative genetic variants were based on the methylation signal displaying a tri- or bimodal distribution, a hallmark of genetic variants 520 underlying DNA methylation<sup>102</sup>, as determined using gaphunter<sup>103</sup> set to a threshold of 0.25. 521 522 The eventual number of CpGs used for training the prediction models were 806.308 and 808,815 for VDZ and USTE, respectively. For the validation of the prediction models, raw 523 524 methylation data from the validation cohort was pre-processed together with the discovery 525 cohort using functional normalization and ComBat to mitigate batch effects introduced by the

526 different experimental setup. From the combined dataset, the predictor CpGs were extracted

527 and the prediction model was recalibrated against the discovery dataset where after

528 predictions were made on the validation dataset.

#### 529 Machine learning models: stability selected gradient boosting analyses

530 The machine learning modeling was divided into two steps, namely feature selection and 531 validation (Fig. 1a). Feature selection was performed on the discovery cohort, collected at 532 the AmsterdamUMC, whereas validation was performed on the validation cohort, collected at 533 the John Radcliffe Hospital. During the feature selection procedure, the model was at no 534 point exposed to the validation cohort. To identify baseline epigenetic markers associated with response/non-response to treatment, we implemented a rigorous supervised machine 535 learning approach using stability selected gradient boosting<sup>34,35,104</sup> combined with covered 536 537 information disentanglement (CID)<sup>105</sup>. Gradient boosting is an algorithm for supervised 538 learning, which operates through stepwise improvement of weak learners thereby minimizing 539 the overall prediction error against the observed data. We opted for gradient boosting as it 540 captures linear, non-linear and interaction effects better than traditional linear regression approaches<sup>104</sup>. CID, in conjunction with stability selected gradient boosting, represents an 541 542 approach for feature selection that assigns permutation-based feature importance that, unlike other methods for assigning feature importance, is unbiased by multicollinearity<sup>105</sup>. 543

544 We first removed CpGs with low variance and then applied univariate feature selection using a F-test. Stability selection was subsequently employed to identify reliable biomarkers by 545 546 splitting randomly the discovery data into an 80% training data and a 20% test data using stratified shuffle split and repeating this process 100 times to mitigate overfitting<sup>106</sup>. During 547 548 each split, we computed the CID for each CpG by randomly permuting it 100 times and 549 calculating the mean feature importance and assessing the average effect of permutation on the model's performance (i.e., predicted versus true outcome)<sup>105</sup>. After all 100 iterations, the 550 551 mean feature importance per iteration was averaged and compared against a randomly 552 generated noise variable that was included throughout the entire modeling process where 553 CpGs with an aggregated feature importance ranked above a random variable were termed 554 predictor CpGs and retained for future analyses.

Having determined the predictor CpGs, we subsequently validated the predictive
performance internally and externally. Internal validation was performed by extracting the
predictor CpGs, training an ensemble of 100 gradient boost models on the 80% discovery
training data and utilizing all models to predict against the withheld 20% discovery test data.
External validation was performed using a similar approach where the discovery and

validation cohort were merged, the predictor CpGs extracted, and an ensemble of 100

- 561 models trained on the discovery cohort. The resultant models were then requested to predict
- the response in the external validation cohort. In both cases, the output of each model
- yielded a prediction score on a scale of 0 to 1 per sample. The prediction scores were
- aggregated by calculating the mean prediction score per sample, representing the final,
- 565 ensembled, output of the model. This final prediction score was used to calculate the
- receiver operator characteristic (ROC) to assess performance. The resultant prediction
- 567 scores were subsequently converted into classes by freezing the model at the Youden index,
- thereby balancing the true positive rate relative to the false positive rate. Analyses were not
- 569 conducted separately for males and females as the cohorts would become too small.
- 570 Aforementioned analyses were performed in Python (v3.10) (https://www.python.org), with
- 571 packages scikit-learn and xgboost for the model development.

### 572 In silico DNA methylation analysis

Differential methylation analyses were performed in R using limma<sup>107</sup> (v3.46) and eBaves<sup>108</sup>. 573 574 Separate analyses were run either regressing against the slide and slide position only, or in combination with common confounding variables: age, sex, smoking behavior and the 575 estimated blood cell distribution<sup>109,110</sup>. The blood cell distribution was estimated using the 576 method described by Houseman et al.<sup>109</sup> and implemented by Salas et al.<sup>110</sup> for the Illumina 577 578 HumanMethylation EPIC BeadChip array, where methylation profiles of the current data are 579 compared against a reference methylation profiles of cell-sorted neutrophils, B cells, 580 monocytes, NK cells, CD4+ T cells and CD8+ T cells, enabling the inference of the cellular 581 composition. Intra-class correlation analyses were performed by conducting a two-way, 582 mixed, consistency analysis comparing samples obtained during response assessment with 583 samples obtained pretreatment using irr (v0.84.1). Statistical significance was defined as a 584 false discovery rate-adjusted p-value < 0.05. Visualizations were generated using ggplot2<sup>111</sup> 585 (v3.3.5).

586 RNA expression and data processing

587 Transcriptomic analyses was conducted through RNA sequencing, wherein mRNA was 588 extracted utilizing the QIAsymphony system, converted into cDNA and sequenced in a 589 paired-end format on the Illumina NovaSeq6000 at the Amsterdam UMC Core Facility 590 Genomics, generating a dataset comprising 40 million 150 bp-reads. Following that, *in silico* 591 data processing was orchestrated in Snakemake where read quality was assessed using 592 FastQC (v0.11.8) and summarized using MultiQC (v1.0)<sup>92,112</sup>. Raw reads were aligned to the 593 human genome (GRCh38) using the STAR aligner (v2.7.0), with annotations provided by the

594 Ensembl v95 annotation. Post-alignment processing was done in SAMtools (v1.9), followed

595 by read counting using the featureCounts function from the Subread package (v1.6.3)<sup>113-115</sup>.

- 596 Differential expression analysis (DE) analysis, was carried out within the R statistical
- 597 environment (v4.3) using the Bioconductor package DESeq2 (v1.38.3). We specifically
- 598 focused on genes associated with the predictor CpG loci based on the latter's location in
- 699 either promoter or enhancer regions. Differentially expressed genes (DEGs) were identified
- 600 based on their significant differences, defined as those with a Benjamini–Hochberg-adjusted
- 601 p-value <0.05. Visualization of the results was accomplished using ggplot2 (v3.4.0)<sup>116</sup>.

#### 602 Sample size estimation

603 We based our sample size on an initial pilot experiment and the calculations performed by 604 Tsai and Bell<sup>80</sup> where we maintained a nominal p-value threshold of 0.05. A pilot experiment 605 using a subset of VDZ treated patients (7 R and 5 NR) indicated on average that the most 606 differentially methylated CpGs presented a mean difference in percentage methylation of 607 10% when comparing R with NR. We subsequently consulted the power calculations 608 reported by Tsai and Bell<sup>80</sup>, who conducted a case-control epigenome wide simulation study. 609 Assuming an approximately equal number of cases and controls and a mean difference in 610 percentage methylation of at least 10% at a nominal p-value threshold of 0.05, a statistical 611 power of at least 80% would be achieved if we included 40 patients (20 R and 20 NR) per 612 drug. To further eliminate the possibility of being underpowered, we aimed to collect at least 613 60 patients for the discovery cohort per drug, which would be supplemented by at least 20 614 patients for the validation cohort.

#### 615 Statistical analysis of clinical variables

616 Baseline characteristics of all included patients were summarized using descriptive statistics. 617 Categorical variables are presented as percentages and continuous variables as median 618 annotated with the interguartile range (IQR). Differences in distribution between responders, 619 non-responders and the different cohorts were assessed using a chi-square test (categorical 620 variables) or Mann-Whitney U (continuous variables). Two-tailed probabilities were used with 621 a p-value ≤0.05 were considered statistically significant. Analyses of clinical data were 622 performed in IBM SPSS statistics (v26). To estimate the probability of a patient responding to 623 either VDZ or USTE after being predicted to be a responder, we calculated the post-test 624 probability using the following formulas:

625 (1) pre test odds =  $\frac{\text{pre test probability}}{1-\text{pre test probability}}$ 

626 (2) likelihood ratio = 
$$\frac{sensitivity}{1-specificity}$$

(4) post test probability = 
$$\frac{\text{post test odds}}{1}$$

(4) post test probability 
$$-\frac{1}{post test odds+1}$$

The pre-test probabilities were obtained from the largest VDZ<sup>7</sup>, and USTE<sup>8</sup> treatment-

response studies to date. The sensitivity and specificity were calculated by determining the

- number of true positives, true negatives, false positives and false negatives when predicting
- 632 response in the validation cohort.

## 633 Data availability

628

- The raw DNA methylation- (.idat) and gene expression (.fastq.gz) data alongside the de-
- 635 identified patient metadata as reported on in this study have been published under controlled
- access for research purposes at the European Genome-phenome Archive (EGA). The DNA
- 637 methylation data for the VDZ discovery cohort can be found under accession ID:
- 638 EGAD00010002651. The DNA methylation data for the VDZ validation cohort can be found
- under accession ID: EGAD00010002652. The DNA methylation data for the USTE discovery
- 640 cohort can be found under accession ID: EGAD00010002649. The DNA methylation data for
- the USTE validation cohort can be found under accession ID: EGAD00010002650. The
- 642 RNA-sequencing data for the VDZ discovery cohort can be found under accession ID:
- 643 EGAD5000000385. The RNA-sequencing data for the USTE discovery cohort can be found
- under accession ID: EGAD5000000386.

## 645 Code availability

- 646 All Snakemake, bash calls and R scripts have been made available on GitHub and can be
- 647 found at https://github.com/ND91/HGPRJ0000008 EPICCD multi drug.git. The machine
- 648 learning modeling was performed using proprietary algorithms founded on the same
- 649 statistical principles as those of gradient boosting, permutation importance, and covered
- 650 information disentanglement. The code for these techniques is openly available at
- 651 <u>https://xgboost.ai</u> and <u>https://github.com/JBPereira/CID</u> or <u>https://scikit-learn.org/stable</u>.

## 2 Tables

- 3 Table 1: Baseline characteristics discovery- and validation cohorts. Values in bold are significant, percentages shown are valid percentages. ADA: adalimumab. VDZ:
- 4 vedolizumab. USTE: ustekinumab. R: responder. NR: non-responder, SD: standard deviation. IQR: interquartile range, CRP: C-reactive protein. FCP: Fecal calprotectin. HBI:
- 5 Harvey Bradshaw Index. SES-CD: simple endoscopic disease activity score, Immunomodulator: azathioprine, mercaptopurine, thioguanine, methotrexate. Anti-TNF:
- 6 infliximab, adalimumab or golimumab.

	Amsterdam	(discovery)		Oxford (val	idation)		Amsterdam	(discovery)		Oxford (val	idation)	
	VDZ R	VDZ NR		VDZ R	VDZ NR		USTE R	USTE NR		USTE R		
	(n=36)	(n=28)	P- val	(n=14)	(n=11)	P- val	(n=30)	(n=32)	P- val	(n=22)	(n=11)	P-val
Sex, n (%), female	17 (47.2)	18 (64.3)	0.17	6 (42.9)	3 (27.3)	0.42	24 (80)	18 (56.3)	0.05	13 (59.1)	5 (45.5)	0.63
Age, years, median (IQR)	36 (25-52)	28 (32-56)	0.98	41 (21-65)	42 (24-70)	0.56	38 (29-56)	35 (23-45)	0.80	43 (35-55)	30 (24- 52)	0.25
Disease duration, years, median (IQR)	12 (3-19)	9 (4-20)	0.80	12 (2-15)	8 (3-17)	0.41	12 (7-23)	10 (5-21)	0.81	15 (6-24)	5 (2-12)	0.05
Ethnic background, n (%), White European	29 (80.6)	19 (67.9)	0.24	13 (92.9)	9 (81.8)	0.80	25 (83.3)	22 (68.8)	0.18	21 (95.5)	7 (87.5)	0.10
CRP, mg/L, median (IQR) <sup>a</sup>	3.9 (2.0- 11.7)	6.2 (3.2- 19.2)	0.26	5.2 (1.4- 11.6)	5.2 (1.3- 23.4)	0.97	5.7 (1.8- 19.2)	7.8 (3.4- 19.1)	0.45	6.1 (1.6- 18.0)	4.8 (2.3- 10.9)	0.30
FCP, ug/g, median (IQR) <sup>b</sup>	1003 (412- 1802)	1322 (389- 2654)	0.79	-	-	-	809 (180- 1599)	729 (221- 2347)	0.69	-	-	-
Total baseline HBI, mean (±SD) or median (IQR) <sup>°</sup>	7.4 (±4.2)	9.3 (±4.9)	0.11	3 (1-8)	4 (1-8)	0.53	8.4 (±5.3)	8.2 (±5.9)	0.90	6 (4-9)	4 (2-8)	0.69
Total baseline SES-CD, median (IQR)	8 (6-12)	10 (5-13)	0.27	7 (6-12)	7 (6-22)	0.92	10 (6-17)	9 (6-14)	0.62	8 (5-16)	8 (3-19)	0.73
Endoscopic evaluation at follow-up	36 (100)	26 (93)	0.19	4 (29)	4 (36)	1.00	29 (97)	29 (91)	0.61	6 (27)	2 (18)	0.69
Disease location, n (%)			0.50			0.21			0.78			0.43
- Ileal disease (L1)	13 (36.1)	8 (28.6)		3 (21)	2 (18)		6 (20.0)	6 (18.8)		7 (32)	5 (46)	
- Colonic disease (L2)	9 (25.0)	5 (17.9)		2 (14)	5 (45)		7 (23.3)	10 (31.3)		8 (36)	2 (18)	
- lleocolonic disease (L3)	14 (38.9)	15 (53.6)		9 (64)	4 (36)		17 (56.7)	16 (50.0)		6 (27)	3 (27)	
- Upper GI involvement (L4)	1 (2.8)	2 (7.1)	0.41	-	-	-	-	-	-	-	1 (9)	0.13
Disease behavior, n (%)			0.60			0.53			0.39			0.06

- Non stricturing non-penetrating (B1)	16 (44.4)	9 (32.1)		9 (82)	10 (91)		10 (33.3)	12 (37.5)		15 (68)	5 (46)	
- Stricturing (P2)	10 (27.8)	10 (35.7)		2 (18)	1 (9)		11 (36.7)	15 (46.9)		5 (23)	2 (18)	
	10 (27.8)	9 (32.1)		-	-		9 (30.0)	5 (15.6)		-	3 (27)	
- Penetrating (B3)	8 (22.2)	11 (39.3)	0.14	1 (7)	2 (18)	0.48	10 (33.3)	12 (37.5)	0.73	6 (27)	3 (27)	0.88
- Perianal disease (p)	0 ()	(0010)	0	. (.)	= ()	0110	()	(0110)	011 0	- ( )	0 ()	0.00
Previous IBD related surgery, n (%)	14 (38.9)	16 (57.1)	0.15	4 (28.6)	4 (36.4)	0.88	23 (76.7)	21 (65.6)	0.34	11 (50)	7 (63)	0.29
Concomitant medication, n (%)												
- Immunomodulators	2 (5.6)	2 (7.1)	0.80	-	2	-	1 (3.3)	-	0.23	1	-	-
- Prednisone taper scheme	-	-		-	-	-	7 (23.3)	4 (12.5)	0.26	-	-	-
Previous treatment exposure, n (%)												
- Immunomodulators	28 (77.8)	24 (85.7)	0.42	13 (92.9)	8 (72.7)	0.17	29 (96.7)	32 (100)	0.23	17 (77.3)	5 (45.5)	0.07
- Anti-TNFs	24 (66.7)	25 (89.3)	0.03	5 (35.7)	7 (63.9)	0.25	30 (100)	31 (96.9)	0.25	14 (63.6)	7 (63.3)	1.00
- Vedolizumab	-	-	-	-	-	-	12 (40.0)	14 (43.8)	0.77	2 (9.1)	3 (27.3)	0.15
- Ustekinumab	2 (5.6)	7 (25.0)	0.03	1 (7.1)	6 (54.5)	0.01	-	-	-	-	-	-
Smoking, n (%) <sup>d</sup>												
- Active	6 (17.1)	2 (7.1)	0.22	3 (21.4)	1 (9.1)	0.30	6 (20)	5 (15.6)	0.65	5 (22.7)	1 (9.1)	0.24

8 **Table 2.** Predictive performance metrics of the prognostic biomarkers on the discovery cohort acquired at the AmsterdamUMC (n=126) and the validation cohort acquired at

9 the John Radcliffe Hospital (n=58). TP = True positives. TN = True negatives. FP = False positives. FN = False negatives. AUC = Area under the receiver operator

0 characteristic curve. VDZ: vedolizumab. USTE: ustekinumab.

	VDZ discovery	VDZ validation	USTE discovery	USTE validation
ТР	33	10	27	16
тл	22	8	29	8
FP	4	4	2	3
FN	3	3	2	6
AUC	0.87	0.75	0.89	0.75
Recall	0.92	0.77	0.93	0.73
Precision	0.89	0.71	0.93	0.84
F1-score	0.90	0.74	0.93	0.78

1

## 663 Legends

#### 664 Figures

Fig. 1: Predictive model using stability selected gradient boosting for response to therapy. a) An overview of the feature selection and supervised machine learning approach for predicting response to VDZ and USTE as

667 used in the current study. Int. train: Internal training set. Int. test: Internal test set. ROC: Receiver operator

668 characteristic. **b)** Receiver operating characteristics plots showing the mean area under the curve (AUC)

669 performance of the discovery (n=126) and validation (n=58) cohorts. c) Left: radar plots presenting the

570 standardized difference in methylation between R (purple) and NR (green) for the top 15 predictor CpGs. Right:

671 Aggregated feature importance of the top 15 predictor CpGs.

672 Fig. 2: Longitudinal stability analyses. a) Volcano plot representing the differential methylation analyses when 673 comparing into treatment (T2) with pretreatment (T1) where grey dots represent CpG loci located on the Illumina 674 HumanMethylation EPIC BeadChip array and black dots represent response-associated predictor CpGs. X-axis 675 represents mean difference in percentage methylation, Y-axis represents the statistical significance as depicted 676 in  $-\log_{10}(p-value)$  with a dashed line at p-value = 0.05. b) Scatterplot showing the correlation of differential DNA 677 methylation between R and NR pretreatment (T1) and into treatment (T2). Grey dots represent CpG loci located 678 on the Illumina HumanMethylation EPIC BeadChip array and black dots represent response-associated predictor 679 CpGs. c) Boxplot of the two-way, consistency, intra-class correlation (ICC) coefficients of the predictor CpGs 680 calculated when comparing pretreatment and into treatment as well as the ICC coefficients of the predictor CpGs obtained from a previous study on long-term stability of DNA methylation in IBD patients<sup>53</sup>. The vertical dashed 681 682 grey lines represent classification boundaries introduced by Koo and  $Li^{37}$ , with blocks representing poor (ICC < 683 0.5), moderate  $(0.5 \le ICC < 0.75)$ , good  $(0.75 \le ICC < 0.9)$ , and excellent  $(0.9 \ge ICC)$ . d) Receiver operating 684 characteristic plots representing the predictive performance into treatment (T2: black) and pre-treatment (T1: 685 grey) as reference.

**Fig. 3: Analyses of potential confounding variables. a)** Volcano plot representing the change in responseassociated differential methylation when correcting for the potential confounding variables age, sex, and estimated cellular composition (black) or not (grey). X-axis represents mean difference in percentage methylation, Y-axis represents the statistical significance as depicted in –log<sub>10</sub>(p-value). The dotted line

- 690 represents a threshold set at p = 0.05. b) Boxplot of the change in effect size after correcting for the confounding
- variables as calculated by  $(\beta_{corrected}, \beta_{uncorrected}) / \beta_{uncorrected}$ . **c)** Receiver operator characteristic curve comparing

the response-prediction model for the CpG model (grey) with the confounder model (blue).

693 Fig. 4: Integrative analyses of predictor CpG-associated genes. a) Scatterplot showing the effect size (Wald 694 statistic) of the response-associated difference in pretreatment (T1; X-axis) and into treatment (T2; Y-axis). Grey 695 dots represent all genes measured, black dots represent non-differentially expressed predictor CpG-associated 696 genes, red, blue and purple dots represent predictor associated genes that are differentially expressed at T1, T2, 697 or T1 and T2, respectively. b) Boxplot of the T1 log<sub>2</sub>(expression) for VDZ response predictor CpG-associated 698 genes TULP4 and RFPL2 stratified by response. c) Scatterplot of the T1 log<sub>2</sub>(expression) of RFPL2 (X-axis) 699 relative to the percentage DNA methylation (Y-axis) for the predictor CpG cg12906381 annotated with the 700 Pearson correlation coefficient and the associated p-value. d) Boxplot of the T1 log<sub>2</sub>(expression) for USTE 701 response predictor CpG-associated genes MRC1 and TMEM191B stratified by response. e) Scatterplot of the T1 702 log<sub>2</sub>(expression) of TMEM191B (X-axis) relative to the percentage DNA methylation (Y-axis) for the predictor

- 703 CpG cg13982436 annotated with the Pearson correlation coefficient and the associated p-value. f) Boxplot of the
- T2 log<sub>2</sub>(expression) for VDZ response predictor CpG-associated genes *MCM*2 and *RFPL2* stratified by response.
- **g)** Scatterplot of the T2 log<sub>2</sub>(expression) of *RFPL2* (X-axis) relative to the percentage DNA methylation (Y-axis)
- for the predictor CpG cg12906381 annotated with the Pearson correlation coefficient and the associated p-value.
- 707 h) Boxplot of the T2 log<sub>2</sub>(expression) for USTE response predictor CpG-associated genes POTEF, HDAC4,
- 708 PARP4 and MARK3 stratified by response.

#### 709 Supplementary Tables

- 710 **Supplementary Table 1**: Differential methylation summary statistics of the VDZ-response predictor CpGs.
- 711 Columns represent the Illumina CpG identifier, the associated HGNC gene symbol, the chromosome, the location
- on the chromosome (build: hg19), the mean difference in percentage methylation between responders and non-
- responders, the nominal p-value associated with the mean difference, the intra-class correlation coefficient
- 714 between pretreatment and during response assessment.
- 715 **Supplementary Table 2**: Differential methylation summary statistics of the USTE-response predictor CpGs.
- 716 Columns represent the Illumina CpG identifier, the mean difference in percentage methylation between
- responders and non-responders, the nominal p-value associated with the mean difference, the genomic
- coordinates on the human genome (build: hg19), the annotated gene name.
- 719 Supplementary Table 3: Clinical characteristics multi-biological failure cohort.
- 720 Supplementary Table 4: Differential expression summary statistics of the VDZ-response predictor CpGs-
- 721 associated genes. Columns represent the Ensembl gene ID, the HGNC gene name, the mean difference in
- log2(fold change) between responders and non-responders and the nominal p-value associated with the meandifference.
- 724 Supplementary Table 5: Differential expression summary statistics of the USTE-response predictor CpGs-
- 725 associated genes. Columns represent the Ensembl gene ID, the HGNC gene name, the mean difference in
- log2(fold change) between responders and non-responders and the nominal p-value associated with the meandifference.

#### 728 Supplementary Figures

- 729 Supplementary Fig. 1: Longitudinal differential methylation of vedolizumab response-associated predictor CpGs.
- 730 Individual boxplots and temporal stability of the 25 VDZ-associated predictor CpGs over time. Top: jitterplot
- visualization with samples obtained from the same donor connected by a dotted line annotated with the two-way
- 732 consistency intra-class correlation coefficient and the 95% confidence intervals. Bottom: boxplot visualization
- 733 grouped by response and stratified by timepoint. Annotations include nominal p-value as determined through
- 734 response-associated differential methylation analyses for samples obtained pretreatment (T1) or during response
- 735 assessment (T2). Green and red represent responders (R) and non-responders (NR), respectively.
- 736 Supplementary Fig. 2: Longitudinal differential methylation of ustekinumab response-associated predictor
- 737 CpGs. Individual boxplots and temporal stability of the 68 USTE-associated predictor CpGs over time. Top:
- jitterplot visualization with samples obtained from the same donor connected by a dotted line annotated with the
- two-way consistency intra-class correlation coefficient and the 95% confidence intervals. Bottom: boxplot
- visualization grouped by response and stratified by timepoint. Annotations include nominal p-value as determined
- through response-associated differential methylation analyses for samples obtained pretreatment (T1) or during
- 742 response assessment (T2). Green and red represent responders (R) and non-responders (NR), respectively.

743 Supplementary Fig. 3: Stratified prediction analyses. Receiver operating characteristics plots showing the mean 744 area under the curve (AUC) performance of the validation cohort patients that were a) assessed using either the 745 strict (NVDZ = 8, NUSTE = 8; blue) or modified (NVDZ =17, NUSTE = 25; pink) response criteria, and b) either 746 anti-TNF exposed (NVDZ = 12, NUSTE = 21; black) or non-exposed (NVDZ = 13, NUSTE = 12; yellow) for VDZ 747 (left) and USTE (right).

- 748 Supplementary Fig. 4: Analyses of markers of IBD-associated inflammation. Volcano plot representing the
- differential methylation analyses regressing against a) C-reactive protein (CRP) and b) fecal calprotectin (FCP)
- 750 pretreatment (T1) for VDZ (left) and USTE (right). Grey dots represent all CpG loci located on the Illumina
- 751 HumanMethylation EPIC BeadChip array and black dots represent response-associated predictor CpGs. X-axis
- represents mean difference in percentage methylation, Y-axis represents the statistical significance as depicted
- in -log10(p-value). CpGs with a nominal p-value < 0.05 are annotated.

## 755 **References**

- de Souza, H.S. & Fiocchi, C. Immunopathogenesis of IBD: current state of the art.
   *Nat Rev Gastroenterol Hepatol* **13**, 13-27 (2016).
- Liu, J.Z., *et al.* Association analyses identify 38 susceptibility loci for inflammatory
   bowel disease and highlight shared genetic risk across populations. *Nat Genet* 47,
   979-986 (2015).
- Alsoud, D., Vermeire, S. & Verstockt, B. Biomarker discovery for personalized
  therapy selection in inflammatory bowel diseases: Challenges and promises. *Curr Res Pharmacol Drug Discov* 3, 100089 (2022).
- Juillerat, P., Grueber, M.M., Ruetsch, R., Santi, G., Vuillemoz, M. & Michetti, P.
  Positioning biologics in the treatment of IBD: A practical guide Which mechanism of action for whom? *Curr Res Pharmacol Drug Discov* 3, 100104 (2022).
- 5. Loftus, E.V., Jr., *et al.* Upadacitinib Induction and Maintenance Therapy for Crohn's
  Disease. *N Engl J Med* 388, 1966-1980 (2023).
- D'Haens, G., *et al.* Risankizumab as induction therapy for Crohn's disease: results
  from the phase 3 ADVANCE and MOTIVATE induction trials. *Lancet* **399**, 2015-2030 (2022).
- 772 7. Lowenberg, M., *et al.* Vedolizumab Induces Endoscopic and Histologic Remission in 773 Patients With Crohn's Disease. *Gastroenterology* **157**, 997-1006 e1006 (2019).
- 8. Sands, B.E., *et al.* Ustekinumab versus adalimumab for induction and maintenance
  therapy in biologic-naive patients with moderately to severely active Crohn's disease:
  a multicentre, randomised, double-blind, parallel-group, phase 3b trial. *Lancet* 399,
  2200-2211 (2022).
- 778 9. Colombel, J.F., *et al.* Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* **362**, 1383-1395 (2010).
- Dulai, P.S., *et al.* Development and Validation of Clinical Scoring Tool to Predict
   Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. *Clin Gastroenterol Hepatol* 18, 2952-2961 e2958 (2020).
- Verstockt, B., *et al.* Expression Levels of 4 Genes in Colon Tissue Might Be Used to
   Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy
   for Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol* 18, 1142-1151 e1110
   (2020).
- Verstockt, B., *et al.* Low TREM1 expression in whole blood predicts anti-TNF
   response in inflammatory bowel disease. *EBioMedicine* 40, 733-742 (2019).
- Verstockt, B., *et al.* DOP70 An integrated multi-omics biomarker predicting
  endoscopic response in ustekinumab treated patients with Crohn's disease. *Journal*of Crohn's and Colitis 13, S072-S073 (2019).
- Soendergaard, C., Seidelin, J.B., Steenholdt, C. & Nielsen, O.H. Putative biomarkers
  of vedolizumab resistance and underlying inflammatory pathways involved in IBD. *BMJ Open Gastroenterol* 5, e000208 (2018).
- Ananthakrishnan, A.N., *et al.* Gut Microbiome Function Predicts Response to Antiintegrin Biologic Therapy in Inflammatory Bowel Diseases. *Cell Host Microbe* 21, 603-610 e603 (2017).
- Lee, J.W.J., *et al.* Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. *Cell Host Microbe* 29, 1294-1304 e1294 (2021).
- Stevens, T.W., *et al.* Systematic review: predictive biomarkers of therapeutic
  response in inflammatory bowel disease-personalised medicine in its infancy. *Aliment Pharmacol Ther* 48, 1213-1231 (2018).
- 80418.Gisbert, J.P. & Chaparro, M. Predictors of Primary Response to Biologic Treatment805[Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel806Disease: From Basic Science to Clinical Practice. J Crohns Colitis 14, 694-709807(2020).

808 809	19.	Zilbauer, M. & Heuschkel, R. Disease Prognostic Biomarkers in Inflammatory Bowel Diseases-A Reality Check. <i>J Crohns Colitis</i> <b>16</b> , 162-165 (2022).
810 811	20.	Bird, A. DNA methylation patterns and epigenetic memory. <i>Genes Dev</i> <b>16</b> , 6-21 (2002).
812 813	21.	Kaluscha, S., <i>et al.</i> Evidence that direct inhibition of transcription factor binding is the prevailing mode of gene and repeat repression by DNA methylation. <i>Nat Genet</i> <b>54</b> , 1805 (2022)
814 815 816	22.	de Mendoza, A., <i>et al.</i> Large-scale manipulation of promoter DNA methylation reveals context-specific transcriptional responses and stability. <i>Genome Biol</i> <b>23</b> , 163
817 818	23.	(2022). Hornschuh, M., Wirthgen, E., Wolfien, M., Singh, K.P., Wolkenhauer, O. & Dabritz, J.
819		The role of epigenetic modifications for the pathogenesis of Crohn's disease. <i>Clin</i>
820 921	24	Epigerietics 13, 108 (2021). Deeny P.C. Dammi M. Claud E. & Shen J. Enigeneme. A mediator for best
821	24.	microbiome crosstalk. Semin Perinatol 45, 151455 (2021)
823	25	Qin Y & Wade P A Crosstalk between the microbiome and epigenome: messages
824	20.	from bugs. <i>J Biochem</i> <b>163</b> . 105-112 (2018).
825	26.	Li, Y., <i>et al.</i> Intestinal mucosa-derived DNA methylation signatures in the penetrating
826		intestinal mucosal lesions of Crohn's disease. <i>Sci Rep</i> <b>11</b> , 9771 (2021).
827	27.	Sadler, T., et al. Genome-wide analysis of DNA methylation and gene expression
828		defines molecular characteristics of Crohn's disease-associated fibrosis. Clin
829		Epigenetics 8, 30 (2016).
830	28.	Adams, A.T., et al. Two-stage Genome-wide Methylation Profiling in Childhood-onset
831		Crohn ☐s Disease Implicates Epigenetic Alterations at the VMP1/MIR21 and HLA
832		Loci. Inflammatory Bowel Diseases <b>20</b> , 17841793 (2014).
833	29.	Ventham, N.T., et al. Integrative epigenome-wide analysis demonstrates that DNA
834		methylation may mediate genetic risk in inflammatory bowel disease. <i>Nature</i>
835	00	Communications 7, 13507 (2016).
836	30.	LI YIM, A.Y.F., et al. Peripheral blood methylation profiling of female Cronn's disease
037 020	31	Patients. Clin Epigenetics <b>6</b> , 05 (2016). Howell K L et al DNA Methylation and Transcription Patterns in Intestinal Epithelial
830	51.	Cells From Pediatric Patients With Inflammatory Rowel Diseases Differentiate
840		Disease Subtypes and Associate With Outcome Gastroenterology <b>154</b> , 585598
841		(2018)
842	32.	Gasparetto, M., et al. Transcription and DNA Methylation Patterns of Blood-Derived
843		CD8(+) T Cells Are Associated With Age and Inflammatory Bowel Disease But Do
844		Not Predict Prognosis. Gastroenterology (2020).
845	33.	Li Yim, A.Y.F., et al. Whole-Genome DNA Methylation Profiling of CD14+ Monocytes
846		Reveals Disease Status and Activity Differences in Crohn's Disease Patients. J Clin
847		<i>Med</i> <b>9</b> (2020).
848	34.	Meinshausen, N. & Bühlmann, P. Stability Selection Journal of the Royal Statistical
849	<u> </u>	Society Series B: Statistical Methodology <b>72</b> , 417/473 (2010).
850	35.	Chen, I. & Guestrin, C. XGBoost: A Scalable Tree Boosting System in
851		Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge
852	26	Discovery and Data Mining 785–794 (New York, 2016).
800 0E1	30.	olterations in patients with inflammatory bowel disease. (Pie Pviv, 2022)
004 855	37	Koo TK & Li MV A Guideline of Selecting and Reporting Intraclass Correlation
856	57.	Coefficients for Reliability Research J Chiropr Med <b>15</b> , 155-163 (2016)
857	38	Tsai P C et al Smoking induces coordinated DNA methylation and gene
858		expression changes in adipose tissue with consequences for metabolic health. <i>Clin</i>
859		Epigenetics <b>10</b> , 126 (2018).
860	39.	Houseman, E.A., Kelsey, K.T., Wiencke, J.K. & Marsit, C.J. Cell-composition effects
861		in the analysis of DNA methylation array data: a mathematical perspective. BMC
862		Bioinformatics 16, 95 (2015).

863 864	40.	Solomon, O., <i>et al.</i> Meta-analysis of epigenome-wide association studies in newborns and children show widespread sex differences in blood DNA methylation.
865	11	Mulai Res-Rev Mulai <b>169</b> (2022).
866	41.	bobbs, K.R., et al. Age-related differences in monocyte DNA methylation and
867	10	Immune function in nearing Kenyan adults and children. Immun Ageing 18, 11 (2021).
868 869	42.	and Severity of Intestinal Inflammation. <i>Gastroenterology</i> (2019).
870	43.	Kappelman, M.D., et al. Real-World Evidence Comparing Vedolizumab and
871		Ustekinumab in Antitumor Necrosis Factor-Experienced Patients With Crohn's
872		Disease. Am J Gastroenterol <b>118</b> , 674-684 (2023).
873	44.	Torres, J., et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical
874		Treatment. J Crohns Colitis 14, 4-22 (2020).
875	45.	Siegel, C., et al. P714 Mucosal healing in CD with vedolizumab versus other
876		biologics: endoscopic outcomes during long-term routine care in a multinational
877		observational study. Journal of Crohn's and Colitis 17, i844-i844 (2023).
878	46.	Danese, S., et al. Treat to target versus standard of care for patients with Crohn's
879		disease treated with ustekinumab (STARDUST): an open-label, multicentre,
880		randomised phase 3b trial. Lancet Gastroenterol Hepatol 7, 294-306 (2022).
881	47.	Feagan, B.G., et al. Rapid Response to Vedolizumab Therapy in Biologic-Naive
882		Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 17, 130-138
883		e137 (2019).
884	48.	Sandborn, W.J., et al. Long-term efficacy and safety of ustekinumab for Crohn's
885		disease through the second year of therapy. Aliment Pharmacol Ther 48, 65-77
886		(2018).
887	49.	Feagan, B.G., et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's
888		Disease. N Engl J Med 375, 1946-1960 (2016).
889	50.	Mishra, N., et al. Longitudinal multi-omics analysis identifies early blood-based
890		predictors of anti-TNF therapy response in inflammatory bowel disease. Genome
891		Med 14, 110 (2022).
892	51.	Lin, S., et al. Whole blood DNA methylation changes are associated with anti-TNF
893		drug concentration in patients with Crohn's disease. J Crohns Colitis (2023).
894	52.	Kennedy, N.A., et al. Predictors of anti-TNF treatment failure in anti-TNF-naive
895		patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
896		Lancet Gastroenterol Hepatol 4, 341-353 (2019).
897	53.	Joustra, V., et al. Long-term Temporal Stability of Peripheral Blood DNA Methylation
898		Profiles in Patients With Inflammatory Bowel Disease. <i>Cell Mol Gastroenterol Hepatol</i>
899		15, 869-885 (2023).
900	54.	Ido, H., et al. Molecular dissection of the alpha-dystroglycan- and integrin-binding
901		sites within the globular domain of human laminin-10. <i>J Biol Chem</i> 279, 10946-10954
902		(2004).
903	55.	Ulazzi, L., et al. Nidogen 1 and 2 gene promoters are aberrantly methylated in human
904		gastrointestinal cancer. Mol Cancer 6, 17 (2007).
905	56.	Yuan, L., et al. RhoJ is an endothelial cell-restricted Rho GTPase that mediates
906		vascular morphogenesis and is regulated by the transcription factor ERG. Blood <b>118</b> ,
907		1145-1153 (2011).
908	57.	Park, S.Y., et al. RhoA/ROCK-dependent pathway is required for TLR2-mediated IL-
909		23 production in human synovial macrophages: Suppression by cilostazol. <i>Biochem</i>
910		Pharmacol <b>86</b> , 1320-1327 (2013).
911	58.	Zeng, R.J., Zhuo, Z.W., Luo, Y.J., Sha, W.H. & Chen, H. Rho GTPase signaling in
912		rheumatic diseases. Iscience 25(2022).
913	59.	Sandi, M.J., et al. MARK3-mediated phosphorylation of ARHGEF2 couples
914		microtubules to the actin cytoskeleton to establish cell polarity. Sci Signal 10(2017).
915	60.	Hu, Y.J., et al. PCGF3 promotes the proliferation and migration of non-small cell lung
916		cancer cells via the PI3K/AKT signaling pathway. Exp Cell Res 400(2021).

917	61.	Zhuang, G.Q., et al. A Novel Regulator of Macrophage Activation miR-223 in
918		Obesity-Associated Adipose Tissue Inflammation. <i>Circulation</i> <b>125</b> , 2892-+ (2012).
919	62.	Jiao, P., et al. miR-223: An Effective Regulator of Immune Cell Differentiation and
920	00	Inflammation. Int J Biol Sci 17, 2308-2322 (2021).
921	63.	vvright, P.B., et al. The mannose receptor (CD206) Identifies a population of colonic
922	<b>.</b>	macrophages in health and inflammatory bowel disease. Sci Rep 11, 19616 (2021).
923	64.	Koelink, P.J., et al. Anti-INF therapy in IBD exerts its therapeutic effect through
924		macrophage IL-10 signalling. <i>Gut</i> <b>69</b> , 1053-1063 (2020).
925	65.	Lu, W., et al. The microRNA miR-22 inhibits the histone deacetylase HDAC4 to
926		promote T(H)17 cell-dependent emphysema. Nat Immunol 16, 1185-1194 (2015).
927	66.	Glauben, R., Sonnenberg, E., Wetzel, M., Mascagni, P. & Siegmund, B. Histone
928		Deacetylase Inhibitors Modulate Interleukin 6-dependent CD4(+) T Cell Polarization
929		in Vitro and in Vivo. <i>J Biol Chem</i> <b>289</b> , 6142-6151 (2014).
930	67.	Brusselle, G.G. & Bracke, K.R. MicroRNA miR-22 drives T(H)17 responses in
931		emphysema. Nat Immunol 16, 1109-1110 (2015).
932	68.	Dou, B., Ma, F.Z., Jiang, Z.Y. & Zhao, L. Blood HDAC4 Variation Links With Disease
933		Activity and Response to Tumor Necrosis Factor Inhibitor and Regulates CD4+T Cell
934		Differentiation in Ankylosing Spondylitis. Front Med-Lausanne 9(2022).
935	69.	Brusselle, G.G. & Bracke, K.R. MicroRNA miR-22 drives T(H)17 responses in
936		emphysema. <i>Nat Immunol</i> <b>16</b> , 1109-1110 (2015).
937	70.	Browning, L.M., et al. TGF-beta-mediated enhancement of TH17 cell generation is
938		inhibited by bone morphogenetic protein receptor 1alpha signaling. Sci Signal
939		<b>11</b> (2018).
940	71.	Kuczma, M. & Kraj, P. Bone Morphogenetic Protein Signaling Regulates
941		Development and Activation of CD4(+) T Cells. Vitam Horm 99, 171-193 (2015).
942	72.	Lu, L., et al. Synergistic effect of TGF-beta superfamily members on the induction of
943		Foxp3(+) Treg. <i>Eur J Immunol</i> <b>40</b> , 142-152 (2010).
944	73.	Park, S.H., et al. Hypermethylation of EBF3 and IRX1 genes in synovial fibroblasts of
945		patients with rheumatoid arthritis. <i>Mol Cells</i> <b>35</b> , 298-304 (2013).
946	74.	Stockinger, B. & Veldhoen, M. Differentiation and function of Th17 T cells. <i>Curr Opin</i>
947		Immunol <b>19</b> , 281-286 (2007).
948	75.	Lyakh, L., Trinchieri, G., Provezza, L., Carra, G. & Gerosa, F. Regulation of
949		interleukin-12/interleukin-23 production and the T-helper 17 response in humans.
950		Immunol Rev <b>226</b> , 112-131 (2008).
951	76.	Zhao, L., Ghetie, D., Jiang, Z. & Chu, CQ. How Can We Manipulate the IL-23/IL-17
952		Axis? Current Treatment Options in Rheumatology 1, 182-196 (2015).
953	77.	Morishima, N., Mizoguchi, I., Takeda, K., Mizuguchi, J. & Yoshimoto, T. TGF-beta is
954		necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem
955		Bioph Res Co <b>386</b> , 105-110 (2009).
956	78.	Rajkovic, A., Lee, J.H., Yan, C. & Matzuk, M.M. The ret finger protein-like 4 gene,
957		Rtpl4, encodes a putative E3 ubiquitin-protein ligase expressed in adult germ cells.
958		Mech Dev 112, 173-177 (2002).
959	79.	Huang, C. Roles of E3 ubiquitin ligases in cell adhesion and migration. Cell Adh Migr
960		<b>4</b> , 10-18 (2010).
961	80.	Isai, P.C. & Bell, J.I. Power and sample size estimation for epigenome-wide
962		association scans to detect differential DNA methylation. Int J Epidemiol 44, 1429-
963	04	1441 (2015).
964	81.	Rees, C. & Penman, I. Has the COVID-19 pandemic changed endoscopy in the UK
965	00	torever / Lancet Gastroenterol Hepatol 8, 6-8 (2023).
966	82.	Lappaiainen, I. & Greally, J.M. Associating cellular epigenetic models with human
96/	00	pnenotypes. <i>Nat Rev Genet</i> <b>18</b> , 441-451 (2017).
968	ბპ.	villicana, S., et al. Genetic impacts on DNA methylation help elucidate regulatory
969		genomic processes. Genome Biol 24, 176 (2023).

970	84.	Yu, A.P., Cabanilla, L.A., Wu, E.Q., Mulani, P.M. & Chao, J. The costs of Crohn's
971		disease in the United States and other Western countries: a systematic review. Curr
972		Med Res Opin <b>24</b> , 319-328 (2008).
973	85.	Mehta, F. Report: economic implications of inflammatory bowel disease and its
974		management. Am J Manag Care 22, s51-60 (2016).
975	86.	Jackson, B., Con, D., Ma, R., Gorelik, A., Liew, D. & De Cruz, P. Health care costs
976		associated with Australian tertiary inflammatory bowel disease care. Scand J
977		Gastroenterol <b>52</b> , 851-856 (2017).
978	87.	Ghosh, N. & Premchand, P. A UK cost of care model for inflammatory bowel disease.
979		Frontline Gastroenterol 6, 169-174 (2015).
980	88.	Rubin, D.T., Mody, R., Davis, K.L. & Wang, C.C. Real-world assessment of therapy
981		changes, suboptimal treatment and associated costs in patients with ulcerative colitis
982		or Crohn's disease. Aliment Pharmacol Ther <b>39</b> , 1143-1155 (2014).
983	89.	Noor, N.M., et al. A biomarker-stratified comparison of top-down versus accelerated
984		step-up treatment strategies for patients with newly diagnosed Cronn's disease
985		(PROFILE): a multicentre, open-label randomised controlled trial. Lancet
986	00	Gastroenterol Hepatol 9, 415-427 (2024).
987	90.	disease
900	01	Ulsease. Varmaira S. Schraibar S. Sandharn W. I. Dubais C. & Putgaarts P. Carrolatian
989	91.	between the Crohn's disease activity and Harvey-Bradshaw indices in assessing
991		Crohn's disease severity. <i>Clin Gastroenterol Hepatol</i> <b>8</b> , 357-363 (2010)
992	92	Molder F et al Sustainable data analysis with Snakemake E1000Res <b>10</b> 33
993	02.	(2021).
994	93.	Arvee, M.J., et al. Minfi: a flexible and comprehensive Bioconductor package for the
995		analysis of Infinium DNA methylation microarrays. <i>Bioinformatics</i> <b>30</b> , 1363-1369
996		(2014).
997	94.	Fortin, J.P., Triche, T.J., Jr. & Hansen, K.D. Preprocessing, normalization and
998		integration of the Illumina HumanMethylationEPIC array with minfi. <i>Bioinformatics</i> 33,
999		558-560 (2017).
1000	95.	Fortin, J.P., Fertig, E. & Hansen, K. shinyMethyl: interactive quality control of Illumina
1001		450k DNA methylation arrays in R. <i>F1000Res</i> <b>3</b> , 175 (2014).
1002	96.	Heiss, J.A. & Just, A.C. Identifying mislabeled and contaminated DNA methylation
1003		microarray data: an extended quality control toolset with examples from GEO. Clin
1004	07	Epigenetics 10, 73 (2018).
1005	97.	Horvath, S. DINA methylation age of numan tissues and cell types. Genome Biol 14,
1006	00	R115 (2013). Forting LD, at all Eurotional normalization of 450k mathulation array data improved
1007	90.	replication in large expect studios. Conomo Piol <b>15</b> , 502 (2014)
1000	00	levierre PM, et al Lineage Specific Conome Architecture Links Enhancers and
1009	99.	Non coding Discass Variants to Target Cone Promotors, Coll <b>167</b> , 1360, 1384, e1310
1010		
1011	100	Johnson WE Li C & Rabinovic A Adjusting batch effects in microarray
1012	100.	expression data using empirical Bayes methods. <i>Biostatistics</i> 8, 118-127 (2007)
1013	101	Leek JT Johnson WF Parker HS Jaffe AF & Storey JD The sya package
1015	1011	for removing batch effects and other unwanted variation in high-throughout
1016		experiments. <i>Bioinformatics</i> <b>28</b> , 882-883 (2012).
1017	102.	Daca-Roszak, P., et al. Impact of SNPs on methylation readouts by Illumina Infinium
1018		HumanMethylation450 BeadChip Array: implications for comparative population
1019		studies. BMC Genomics 16, 1003 (2015).
1020	103.	Andrews, S.V., Ladd-Acosta, C., Feinberg, A.P., Hansen, K.D. & Fallin, M.D. "Gap
1021		hunting" to characterize clustered probe signals in Illumina methylation array data.
1022		Epigenetics Chromatin 9, 56 (2016).
1023	104.	Friedman, J.H. Greedy Function Approximation: A Gradient Boosting Machine. The
1024		Annals of Statistics <b>29</b> , 1189-1232 (2001).

1025 1026 1027	105.	J., P., E., S., A., Z. & E., L. Covered Information Disentanglement: Model Transparency via Unbiased Permutation Importance. in <i>The Thirty-Sixth AAAI</i> <i>Conference on Artificial Intelligence (AAAI-22)</i> (2022).
1028 1029	106.	Demsar, J. & Zupan, B. Hands-on training about overfitting. <i>PLoS Comput Biol</i> <b>17</b> , e1008671 (2021).
1030 1031	107.	Ritchie, M.E., <i>et al.</i> limma powers differential expression analyses for RNA- sequencing and microarray studies. <i>Nucleic Acids Res</i> <b>43</b> , e47 (2015).
1032 1033	108.	Smyth, G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. <i>Stat Appl Genet Mol Biol</i> <b>3</b> , Article3 (2004).
1034 1035	109.	Houseman, E.A., et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics <b>13</b> , 86 (2012).
1036 1037	110.	Salas, L.A., <i>et al.</i> An optimized library for reference-based deconvolution of whole- blood biospecimens assayed using the Illumina HumanMethylationEPIC BeadArray.
1038 1039 1040	111.	Genome Biol <b>19</b> , 64 (2018). Wickham, H. ggplot2: Elegant Graphics for Data Analysis, (Springer-Verlag New York, 2016)
1041 1042 1043	112.	Ewels, P., Magnusson, M., Lundin, S. & Kaller, M. MultiQC: summarize analysis results for multiple tools and samples in a single report. <i>Bioinformatics</i> <b>32</b> , 3047-3048 (2016).
1044 1045	113.	Dobin, A., et al. STAR: ultrafast universal RNA-seq aligner. <i>Bioinformatics</i> <b>29</b> , 15-21 (2013).
1046 1047	114.	Li, H., <i>et al.</i> The Sequence Alignment/Map format and SAMtools. <i>Bioinformatics</i> <b>25</b> , 2078-2079 (2009).
1048 1049 1050	115.	Liao, Y., Smyth, G.K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. <i>Bioinformatics</i> <b>30</b> , 923-930 (2014)
1051 1052	116.	H, W. ggplot2: Elegant Graphics for Data Analysis [Internet]. New York, NY: Springer-Verlag New York (2009).







